stockportfolio.pro
Stocks / IMVT vs LEGN
IMVT vs LEGN
Immunovant, Inc. and Legend Biotech Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Immunovant, Inc. (IMVT) | Legend Biotech Corporation (LEGN) | |
|---|---|---|
| Market cap | $6.6B | $6.5B |
| Revenue (latest FY) | $0 | $1.03B |
| Net income (latest FY) | $-505.61M | $-296.80M |
| Revenue growth (5y CAGR) | — | 106.4% |
| Net margin | — | -28.8% |
| Return on equity | -59.3% | -29.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IMVT — free Open LEGN — freeFrequently asked questions
Which is bigger, IMVT or LEGN?
Immunovant, Inc. is larger by market capitalization — $6.6B versus $6.5B.
Which grows faster, IMVT or LEGN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.